(Q34788240)

English

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

multicenter clinical trial

0 references

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

0 references

magnetic resonance imaging

0 references

Carolyn A. Young

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

G Comi

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

A Pulizzi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M Rovaris

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

O Abramsky

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

T Arbizu

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

A Boiko

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

R Gold

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

E Havrdova

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

S Komoly

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Kw Selmaj

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

B Sharrack

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M Filippi

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

0 references

publication date

1 June 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

371

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

2085-2092

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

9630

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Factor V Leiden related Budd-Chiari syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960918-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)60918-6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18572078%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34788240&oldid=1406255740"